Novo Nordisk's Data at EASD - Analyst Blog
September 15 2011 - 5:45AM
Zacks
Novo Nordisk (NVO) recently
presented data from two trials of its lead diabetes drug, Victoza,
at the European Association for the Study of Diabetes (EASD).
The first trial showed that using Victoza at an early stage in
diabetes treatment of patients with type II diabetes, who had not
received any treatment before or previously received only one oral
anti-diabetic drug (OAD), led to greater improvements in glycaemic
control than those who had been dosed two or more OAD’s.
The second trial showed that when type II diabetes patients
switched from oral treatment with Merck’s (MRK)
Januvia to injectable Victoza (once daily) experienced increased
treatment satisfaction as well as significant reductions in blood
glucose and body weight.
We remind investors that in June this year, Novo Nordisk had
presented data from two extension studies of Victoza at the
American Diabetes Association (ADA). The first study showed that
patients who were given Victoza (once daily) in combination with
metformin experienced better blood sugar control and weight loss
versus other commonly used diabetes drugs like Januvia or
Amylin Pharmaceuticals’ (AMLN)/Eli
Lilly’s (LLY) Byetta.
Novo Nordisk also presented data from another phase late-stage
trial at the ADA, which investigated the effect of adding Levemir
to the existing treatment regimen of Victoza plus metformin. The
trial showed that the Levemir supplement group experienced
improvement in glycemic control, weight loss and lower rate of
hypoglycemia, compared to the group receiving only metformin and
Victoza. When given Victoza alone, more than 60% of patients
achieved the ADA target for blood sugar control. Moreover, the
addition of Levemir helped more patients achieve the ADA target
(80% of patients) without the increases in hypoglycemia and body
weight.
Our Recommendation
So far, we are impressed by Novo Nordisk’s biggest drug
Victoza’s performance. Victoza is doing well both in the US and
Europe. Moreover, we believe that the next-generation insulin
analogues, Degludec and DegludecPlus, also hold significant
importance for long-term growth at Novo Nordisk. Though we are
encouraged by data from Degludec trials, we prefer to remain on the
sidelines until we get more visibility on the approvability of
Degludec and DegludecPlus. We currently have a Neutral
recommendation on Novo Nordisk on a long-term basis. The stock
carries a #3 Rank (short-term “Hold” recommendation).
AMYLIN PHARMA (AMLN): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
Zacks Investment Research
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Apr 2024 to May 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From May 2023 to May 2024